Amgen Inc.
Amgen Reports Strong Third Quarter 2024 Financial Results
Summary
Amgen announced robust financial results for the third quarter of 2024, with total revenues increasing by 23% to $8.5 billion compared to the same period last year. The company reported a 62% increase in GAAP earnings per share (EPS) from $3.22 to $5.22, and a 13% increase in non-GAAP EPS from $4.96 to $5.58. Product sales growth was driven by strong performance in key products such as Repatha, EVENITY, and BLINCYTO. Free cash flow also increased to $3.3 billion. The company's Horizon acquisition significantly contributed to the growth in revenues and expenses.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement